A new Ebola outbreak in Congo is once again testing global health systems, but it is also spotlighting a small group of vaccine developers who have spent the quiet years preparing for noisy ones like this. As health agencies scramble on the…
The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors.
FDA’s New Cast at the Top
The Food…
Investors are quietly building a new playbook: keep riding the AI rocket, but pair it with old‑economy resilience and under‑the‑radar healthcare innovators that actually move the needle in patients’ lives.
When Tech Flies Too Close to the Sun
Wall Street’s love affair…
Nanobiotix’s (NBTX) latest preclinical data suggest that its Nanoprimer technology may do for lipid nanoparticle (LNP) DNA immunotherapy what noise-cancelling headphones did for air travel: make a powerful experience markedly more tolerable. For investors watching the crossroad of oncology and genetic medicines,…
Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did…
If 2024 crowned weight-loss drugs the belle of the healthcare ball, 2025 belongs to the bispecific antibody. What began as a niche in immuno-oncology has evolved into biotech’s most competitive—and potentially lucrative—battleground, drawing fresh capital, dealmaking, and analyst optimism that borders on…
Wall Street shook off its November sulk on Monday, with the major benchmarks staging a rate-cut–hope rally that looked suspiciously like early Christmas cheer delivered by central bankers rather than Santa. The S&P 500 climbed about 1.55% to roughly 6,705.12, the Dow…
Large caps took a hit this week with the Dow 30 ending at 46,245.41, -1.9% & the S&P 500 closed at 6,602.99 equally off 1.9%. The high-beta tech kept the Nasdaq on the defensive for most of the week and fell 2.7%…
In the end, Thursday looked like a market attempting to renegotiate its relationship with AI, tariffs and the Fed all at once—discovering, not for the first time, that even in an age of algorithms and GLP‑1s, gravity still has a vote.
Indexes…
U.S. stocks closed Wednesday looking more contemplative than chaotic, as Wall Street tiptoed into the bell ahead of Nvidia’s after-hours earnings—and then promptly exhaled when the AI titan delivered another blockbuster beat. The S&P 500 and Nasdaq finished modestly higher after shaking…